Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer
CONCLUSIONS: SABR appears to have clinical benefit in oligoprogresssive prostate, lung, and renal patients. However, the optimal management of patients with oligoprogressive disease is still somewhat uncertain due to lack of prospective data. This will hopefully become clearer in the near future with the publication of further randomised trials.PMID:38648995 | DOI:10.1016/j.radonc.2024.110288 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - April 22, 2024 Category: Radiology Authors: Emma Doyle Angus J Killean Stephen Harrow Iain D Phillips Source Type: research
Pan-Cancer Analysis of the Prognostic and Immunological Role of TOMM40 to Identify Its Function in Breast Cancer
In conclusion, we found that TOMM40 has prognostic value in 21 cancers, including breast cancer, by bioinformatics analysis. Based on immune correlation analysis, TOMM40 may also be a potential immunotherapeutic target for the treatment of BRCA. Therefore, our results may provide researchers to further explore the role of MARGs, especially TOMM40, in the developmental process of breast cancer, which may provide new directions and targets for the improvement of prognosis of breast cancer patients and their treatment.PMID:38649557 | DOI:10.1007/s10528-024-10794-6 (Source: Biochemical Genetics)
Source: Biochemical Genetics - April 22, 2024 Category: Genetics & Stem Cells Authors: Yaqing Zhou Xing Wei Lijun Jia Weimiao Li Shuqun Zhang Yonglin Zhao Source Type: research
Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer
Oncol Lett. 2024 Apr 10;27(6):260. doi: 10.3892/ol.2024.14393. eCollection 2024 Jun.ABSTRACTThe C-X-C motif chemokine ligand 8 (CXCL8)-C-X-C chemokine receptor (CXCR)1/2 signalling axis is among numerous mechanisms which stimulate the immune system to defend against tumour growth and influence the tumour microenvironment to promote tumour growth. This pathway plays an important role in the development of a number of cancers including breast cancer (BC). The aim of the present study was to analyse the levels of the chemokine CXCL8 and its receptors, CXCR1 and CXCR2, in the serum of female patients with invasive BC and to as...
Source: Oncology Letters - April 22, 2024 Category: Cancer & Oncology Authors: Sebastian St ępień Marta Smycz-Kuba ńska Celina Kruszniewska-Rajs Joanna Magdalena Gola Jacek Kabut Pawe ł Olczyk Aleksandra Mielczarek-Palacz Source Type: research
Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)
Oncol Lett. 2024 Apr 9;27(6):256. doi: 10.3892/ol.2024.14389. eCollection 2024 Jun.ABSTRACTCluster of differentiation 47 (CD47) is a transmembrane protein that is widely and moderately expressed on the surface of various cells and can have an essential role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis and other related responses by binding to its ligands, integrins, thrombospondin-1 and signal regulatory protein α. The poor prognosis of cancer patients is closely associated with high expression of CD47 in glioblastoma, ovarian cancer, breast cancer, bladder cancer, colon cancer a...
Source: Oncology Letters - April 22, 2024 Category: Cancer & Oncology Authors: Fan Wu Hongyuan Pang Fan Li Mengqing Hua Chuanwang Song Jie Tang Source Type: research
Metastatic breast cancer with double heterozygosity for the < em > BRCA1 < /em > and < em > BRCA2 < /em > genes responding to olaparib: A case report
In conclusion, the present study reported a female patient with double heterozygosity of BRCA1 and BRCA2 who benefited from olaparib monotherapy. Thus, olaparib may be a suitable treatment for such patients.PMID:38646498 | PMC:PMC11027096 | DOI:10.3892/ol.2024.14387 (Source: Oncology Letters)
Source: Oncology Letters - April 22, 2024 Category: Cancer & Oncology Authors: Bin Shao Lijun Di Source Type: research
Breast density quantification in dual-energy mammography using virtual anthropomorphic phantoms
CONCLUSIONS: Our results in virtual phantoms indicate that the material decomposition method can produce accurate VBD measurements if the presence of a third material (skin) is considered. The results from our proof of concept showed agreement between MRI and dual-energy mammography VBD. Assessment of VBD using dual-energy images could provide complementary information in dual-energy mammography and tomosynthesis examinations.PMID:38648734 | DOI:10.1002/acm2.14360 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Gustavo Pacheco Jorge Patricio Castillo-Lopez Yolanda Villase ñor-Navarro Mar ía-Ester Brandan Source Type: research
Social characteristics and social benefit use among premenopausal breast cancer survivors in Denmark: a population-based cohort study
CONCLUSIONS: Use of social benefits reflecting lost ability to work was highest in less educated women and in women living alone.IMPLICATIONS FOR CANCER SURVIVORS: Awareness of these groups is crucial when tailoring efforts to support work participation in cancer survivors.PMID:38647591 | DOI:10.1007/s11764-024-01598-z (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Cathrine F Hjorth Julie A Schmidt D óra K Farkas Deirdre Cronin-Fenton Source Type: research
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation
Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.04.002. Online ahead of print.ABSTRACTFollowing the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchym...
Source: Ann Oncol - April 22, 2024 Category: Cancer & Oncology Authors: S Peters S Loi F Andr é S Chandarlapaty E Felip S P Finn P A J änne K M Kerr E Munzone A Passaro M P érol E F Smit C Swanton G Viale R A Stahel Source Type: research
The Role of Axillary Lymph Node Dissection versus Sentinel Lymph Node Dissection in Breast Cancer Patients with Clinical N2b-N3c Disease Who Receive Adjuvant Radiotherapy
CONCLUSIONS: ALND in patients with advanced nodal disease was not associated with improved survival compared with SLNB for women who receive adjuvant radiotherapy.PMID:38647915 | DOI:10.1245/s10434-024-15280-2 (Source: Ann Oncol)
Source: Ann Oncol - April 22, 2024 Category: Cancer & Oncology Authors: Eric A Roach Christopher R Weil George Cannon Jon Grant Margaret Van Meter Dustin Boothe Source Type: research
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Conclusion: Disease progression was associated with significant increases in HCRU and costs. Delays in progression were associated with lower cumulative healthcare costs. Earlier use of more clinically effective treatments to delay progression may reduce the economic burden among these patients.PMID:38647165 | DOI:10.57264/cer-2023-0166 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 22, 2024 Category: General Medicine Authors: Clara Lam Brandon Diessner Katherine Andrade Sydnie Stackland Leah Park Sandhya Mehta Feng Lin Winghan Jackie Kwong Source Type: research
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
CONCLUSIONS: A single dose of PEG G-CSF is strongly recommended over multiple-dose non-PEG G-CSF therapy for the primary prophylaxis of FN.PMID:38649648 | DOI:10.1007/s10147-024-02504-4 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Tetsuhiro Yoshinami Kazuki Nozawa Takamichi Yokoe Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Yuji Miura Makoto Endo Shingo Yano Dai Maruyama Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito Eishi Baba Nobuaki Ochi Toshio K Source Type: research
Breast density quantification in dual-energy mammography using virtual anthropomorphic phantoms
CONCLUSIONS: Our results in virtual phantoms indicate that the material decomposition method can produce accurate VBD measurements if the presence of a third material (skin) is considered. The results from our proof of concept showed agreement between MRI and dual-energy mammography VBD. Assessment of VBD using dual-energy images could provide complementary information in dual-energy mammography and tomosynthesis examinations.PMID:38648734 | DOI:10.1002/acm2.14360 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Gustavo Pacheco Jorge Patricio Castillo-Lopez Yolanda Villase ñor-Navarro Mar ía-Ester Brandan Source Type: research
Stepwise analysis of thyroid diagnostic modalities with genomic imprinting detection
CONCLUSIONS: Our study demonstrated the significant stepwise diagnostic contributions of standard clinical assessments in the malignancy risk stratification of thyroid nodules. However, the addition of molecular imprinting detection further enabled a more accurate and definitive preoperative evaluation especially for morphologically indeterminate thyroid nodules and cases with potentially discordant results among standard modalities.PMID:38644545 | DOI:10.21037/cco-23-89 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Wanting Yang Ming Yin Jiehong Zhou Yun Zhu Beibei Ye Hui Shi Bingjie Zhang Can Yue Yifeng Zhang Hongxun Wu Haohao Li Xuliang Xia Shufang Yang Buyun Ma Source Type: research
Social characteristics and social benefit use among premenopausal breast cancer survivors in Denmark: a population-based cohort study
CONCLUSIONS: Use of social benefits reflecting lost ability to work was highest in less educated women and in women living alone.IMPLICATIONS FOR CANCER SURVIVORS: Awareness of these groups is crucial when tailoring efforts to support work participation in cancer survivors.PMID:38647591 | DOI:10.1007/s11764-024-01598-z (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Cathrine F Hjorth Julie A Schmidt D óra K Farkas Deirdre Cronin-Fenton Source Type: research
Comprehensive profiling of L1 retrotransposons in mouse
Nucleic Acids Res. 2024 Apr 22:gkae273. doi: 10.1093/nar/gkae273. Online ahead of print.ABSTRACTL1 elements are retrotransposons currently active in mammals. Although L1s are typically silenced in most normal tissues, elevated L1 expression is associated with a variety of conditions, including cancer, aging, infertility and neurological disease. These associations have raised interest in the mapping of human endogenous de novo L1 insertions, and a variety of methods have been developed for this purpose. Adapting these methods to mouse genomes would allow us to monitor endogenous in vivo L1 activity in controlled, experimen...
Source: Cell Research - April 22, 2024 Category: Cytology Authors: Xuanming Zhang Ivana Celic Hannah Mitchell Sam Stuckert Lalitha Vedula Jeffrey S Han Source Type: research
